Title

P226 FRACTION-RCC: a randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC.

Publication/Presentation Date

11-2017

Comments

Was Presented on November 2017 at the 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two in National Harbor, MD.

Disciplines

Hematology | Medical Sciences | Medicine and Health Sciences | Oncology

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Article

This document is currently not available here.

Share

COinS